Shanghai De Novo Pharmatech announced achievement of important First-in-Human milestone in China in phase I Trials with the novel investigational TLR8 agonist DN1508052. This Phase I open-label, multi-center study is designed to investigate the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary antitumor activity of DN1508052 monotherapy in Chinese patients with advanced solid tumors.